+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidance



When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidance



Pharmacoeconomics 31(2): 137-149



There is growing interest internationally in linking reimbursement decisions with recommendations for further research. In the UK, the National Institute for Health and Clinical Excellence (NICE) can issue guidance to approve the routine use of a health intervention, reject routine use or recommend use within a research programme. These latter recommendations have restricted use to 'only in research' (OIR) or have recommended further research alongside routine use ('approval with research' or AWR). However, it is not currently clear when such recommendations are likely to be made. This study aims to identify NICE technology appraisals where OIR or AWR recommendations were made and to examine the key considerations that led to those decisions. Draft and final guidance including OIR/AWR recommendations were identified. The documents were reviewed to establish the characteristics of the technology appraisal, the cost effectiveness of the technologies, the key considerations that led to the recommendations and the types of research required. In total, 29 final and 31 draft guidance documents included OIR/AWR recommendations up to January 2010. Overall, 86 % of final guidance included OIR recommendations. Of these, the majority were for technologies considered to be cost ineffective (83 %) and the majority of final guidance (66 %) specified the need for further evidence on relative effectiveness. The use of OIR/AWR recommendations is decreasing over time and they have rarely been used in appraisals conducted through the single technology appraisal process. NICE has used its ability to recommend technologies within research programmes, although predominantly within the multiple technology appraisal process. OIR recommendations have been most frequently issued for technologies considered cost ineffective and the most frequently cited consideration is uncertainty related to relative effectiveness. Key considerations cited for most AWR recommendations and some OIR recommendations included a need for further evidence on long-term outcomes and adverse effects of treatment.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056930802

Download citation: RISBibTeXText

PMID: 23329429

DOI: 10.1007/s40273-012-0013-6


Related references

Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development. Health Technology Assessment 16(46): 1-323, 2013

Review Of Models Submitted To Nice Medical Technologies Evaluation Programme To Inform A Cost Consequence Template For Use In Medical Technologies Guidance Submissions. Value in Health 20(9): A749-A750, 2017

NICE guidance on ADHD. NICE should produce guidance on infant mental health. BMJ 337: A2288, 2008

What's the evidence that NICE guidance has been implemented? Maybe NICE needs to do more to ensure implementation of guidelines. BMJ 330(7499): 1085, 1085-6, 2005

NICE guidance on ADHD. NICE recommendations are not evidence based and could expose many to unnecessary harm. BMJ 337: A2284, 2008

What's the evidence that NICE guidance has been implemented? More recent data on NICE implementation show different picture. BMJ 330(7499): 1086, 1086, 2005

Assessment of Devices, Diagnostics and Digital Technologies: A Review of NICE Medical Technologies Guidance. Applied Health Economics and Health Policy 2018, 2018

Current application of National Institute for Health and Clinical Excellence (NICE) guidance in the management of patients with severe psoriasis: a clinical audit against NICE guidance in seven National Health Service specialist dermatology units in England. Clinical and Experimental Dermatology 36(6): 602-606, 2011

Adopting medical technologies and diagnostics recommended by NICE: the Health Technologies Adoption Programme. Annals of the Royal College of Surgeons of England 96(5): 400-401, 2014

NICE guidance does not currently recommend e-cigarettes. BMJ 348: G315, 2016

Examining the implementation of NICE guidance: cross-sectional survey of the use of NICE interventional procedures guidance by NHS Trusts. Implementation Science 10: 93, 2016

NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 323(7324): 1300-1303, 2001

Review of Economic Submissions to NICE Medical Technologies Evaluation Programme. Applied Health Economics and Health Policy 14(6): 623-634, 2016

Evidence based public health: A review of the experience of the National Institute of Health and Clinical Excellence (NICE) of developing public health guidance in England. Social Science & Medicine 71(6): 1056-1062, 2010

NICE Medical Technologies Guidance: a novel and rigorous methodology to address a new health technology assessment challenge. Applied Health Economics and Health Policy 10(5): 295-297, 2013